01—Abstract
Summary
Summary of the 10-K/A filed October 21, 2008. Cited figures are marked; the original filing is the authoritative source.
Eli Lilly & Co. filed an amendment to its 2007 10-K on October 20, 2008, primarily to restate its consolidated balance sheets and selected financial data for certain prior periods.
The restatement was necessitated by an adjustment to the company's reserve for future product returns, specifically related to the methodology for calculating this reserve in accordance with SFAS 48. The company states that this restatement had no effect on its income, cash flows, or liquidity, and the effects on its financial position were immaterial.
In addition, certain disclosures regarding deferred tax assets, valuation allowances, and uncertain tax positions were modified, also without impacting the company's financial statements. The filing also provides updates on legal and regulatory matters, including ongoing patent litigation and investigations into marketing and promotional practices, particularly concerning the drug Zyprexa.
02—Key points
Key Highlights
- Restatement of prior period financial statements due to an adjustment in the reserve for future product returns.
- The restatement had no impact on income, cash flows, or liquidity, and the effects on financial position were deemed immaterial.
- Modifications were made to disclosures concerning deferred tax assets, valuation allowances, and uncertain tax positions.
- The company is involved in significant patent litigation, particularly challenging generic manufacturers of its key products like Evista, Gemzar, and Strattera.
- Eli Lilly is also facing investigations related to its marketing and promotional practices, particularly concerning Zyprexa, Prozac, and Evista.
- Substantial charges have been recorded for Zyprexa product liability litigation, with ongoing legal battles and settlements impacting financial results.
- The company reported strong sales growth in 2007, driven by key products such as Cymbalta and the acquisition of ICOS (maker of Cialis).
03—One dollar
04—Financials
Financial Highlights
Figures from 10-K/AFY2007filed October 21, 200805—Questions
Frequently Asked Questions
What is the primary reason for this filing being an amendment (10-K/A)?
This filing is an amendment to restate the consolidated balance sheets and selected financial data for prior periods due to an adjustment in the company's reserve for future product returns. This adjustment was identified as needing correction based on a revised methodology.
What was the impact of the restatement on Eli Lilly's financial performance?
Eli Lilly stated that the restatement had no effect on its income, cash flows, or liquidity. The financial position effects at the end of the restated periods were also considered immaterial.
Are there any significant legal or regulatory issues discussed in this filing?
Yes, the filing details ongoing patent litigation related to key products such as Evista, Gemzar, and Strattera, as well as challenges to Zyprexa patents in various international markets. Additionally, the company is subject to investigations regarding its marketing and promotional practices, particularly concerning Zyprexa.
How did the ICOS acquisition impact the financial results?
The acquisition of ICOS, completed in January 2007, brought the full value of Cialis to Eli Lilly and contributed significantly to the company's sales growth in 2007. The acquisition also resulted in substantial acquired in-process research and development (IPR&D) charges.
What is the company's outlook for sales and earnings in 2008?
For the full year 2008, Eli Lilly projected earnings per share in the range of $3.80 to $3.95 and expected sales to grow in the mid-to-high single digits, driven by key products like Cymbalta, Cialis, Byetta, Alimta, and Humalog.
06—Continue